2025's projected top line of between $61 billion and $64 billion remains markedly below 2022's record-breaking peak revenue ...

The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.

The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead ...

Although it is the leading infectious cause of birth defects, patients and some doctors know little about cytomegalovirus.

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) and the Department of Commerce (DOC) ...

Overview:  Focuses on high-dividend stocks that offer stable income and long-term holding potential.Highlights companies with ...

Private credit assets under management will move from roughly $13 trillion today to close to $20 trillion in the next four ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.

Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...

The U.S. plans to negotiate the prices of 15 more medications covered by Medicare, including two of Eli Lilly's top-selling ...